Modality
mAb
MOA
HPK1i
Target
JAK2
Pathway
Amyloid
Urothelial CaAS
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
Mar 2017
→ Mar 2029
Phase 2Current
NCT05613616
756 pts·Urothelial Ca
2017-03→2029-03·Completed
756 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-163.0y awayPh3 Readout· Urothelial Ca
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Complet…
Catalysts
Ph3 Readout
2029-03-16 · 3.0y away
Urothelial Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05613616 | Phase 2/3 | Urothelial Ca | Completed | 756 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 |